IsoRay, a provider of medical radioisotope technology, has received CE mark approval for its GliaSite radiation therapy system.

GliaSite radiation therapy system is a balloon catheter device used for the treatment of brain cancer.

The system’s balloon catheter facilitates physicians to treat more patients with brachytherapy or internal radiation and provides important benefits over other radiation treatment options.

IsoRay chairman and CEO Dwight Babcock said the introduction of GliaSite allows the company to pursue other distribution opportunities in countries not previously serviced.

"This historic moment completes the last requirement essential to initiate the international launch of our GliaSite® radiation therapy system," Babcock said.

IsoRay also manufactures FDA-cleared Cesium-131 used to treat brain, colorectal, gynecologic head and neck, lung, prostate and ocular melanoma cancers.